(Curtin University. Medical School)
(University of Montpellier. Department of Respiratory Diseases)
(Humanitas University. Department of Biomedical Sciences)
(Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT))
| Fecha: |
2025 |
| Resumen: |
Introduction: We compared the real-world effectiveness of initiating beclometasone dipro- pionate/formoterol fumarate (BDP/FOR) versus fluticasone furoate/vilanterol (FF/VI) in a general practice (GP) asthma cohort in England. Methods: Patients newly initiating BDP/ FOR or FF/VI between 1 December 2015 and 28 February 2019 (index), were selected from anonymised Clinical Practice Research Data- link data. Baseline was < 12 months pre-index with ≤ 12 months follow-up post-index. Eli- gible patients were aged ≥ 18 years at index, had diagnosed asthma, ≥ 1 FF/VI or BDP/FOR prescription, medical records eligible for link- age to secondary care data and continuous GP- registration ≥ 12 months pre-index. Patients with chronic obstructive pulmonary disease, ≥ 1 fixed-dose inhaled corticosteroid/long-act- ing β2 -agonist, single-inhaler triple or biologic therapy at index were excluded. The primary study outcome was asthma exacerbation rate. Secondary outcomes included medication per- sistence and oral corticosteroid (OCS) use. Pro- pensity scores were generated for each treatment comparison; inverse probability of treatment weighting adjusted for confounding in base- line characteristics between groups, applied to each outcome separately. Analyses considered intercurrent events (ICEs; treatment switching, discontinuation, loss to follow-up, death, rescue medication use). Results: Weighted group standard mean differ- ences showed adequate balance for most covari- ates. Patients initiating BDP/FOR (n = 46,809) and FF/VI (n = 3773) had numerically similar exacerbation rates per person per year (PPPY) while-on index treatment [measuring outcome until ICE; BDP/FOR, 0. 1479 (n = 31,715); FF/VI, 0. 1338 (n = 2547); rate ratio 0. 9048, p = 0. 2841]. Patients continuing uninterrupted index treat- ment for 12 months had a lower exacerbation rate PPPY for FF/VI [0. 0681 (n = 384)] than BDP/FOR [0. 1104 (n = 3342); rate ratio, 0. 6162 (p = 0. 0293)]. For patients initiating FF/VI ver- sus BDP/FOR, treatment persistence was greater [hazard ratio, 0. 76 (p < 0. 0001)]. Conclusion: Overall, patients initiating FF/ VI and BDP/FOR had numerically similar exacerbation rates; of the patients continuing 12 months' uninterrupted treatment, the FF/VI group had a lower exacerbation rate versus BDP/ FOR. Patients initiating FF/VI were less likely to discontinue treatment than those initiating BDP/FOR. |
| Nota: |
This article is licensed under a Creative Commons Attribution-NonCommer- cial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, pro- vide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the cop- yright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/. |
| Nota: |
This study, including study design, data collection, analysis and interpre- tation, medical writing and submission sup- port for the manuscript, was funded by GSK (221602). The journal's Rapid Service and Open Access Fees were funded by GSK. |
| Derechos: |
Aquest material està protegit per drets d'autor i/o drets afins. Podeu utilitzar aquest material en funció del que permet la legislació de drets d'autor i drets afins d'aplicació al vostre cas. Per a d'altres usos heu d'obtenir permís del(s) titular(s) de drets.  |
| Lengua: |
Anglès |
| Documento: |
Article ; recerca ; Versió publicada |
| Materia: |
Asthma ;
Beclometasone dipropionate/formoterol fumarate ;
Comparative effectiveness ;
Fluticasone furoate/vilanterol ;
General practice ;
Real-world data ;
United Kingdom |
| Publicado en: |
Advances in Therapy, Vol. 42 (September 2025) , p. 5960-5977, ISSN 1865-8652 |
| Obra relacionada: |
Woodcock, Ashley [et al.]. «Correction to : Real-World Comparative Effectiveness Study in Patients with Asthma Initiating Fluticasone Furoate/Vilanterol or Beclometasone Dipropionate/ Formoterol Fumarate in General Practice in England». Advances in Therapy, Vol. 42 (November 2025), p. 5978-5979 https://doi.org/10.1007/s12325-025-03407-0 |
visitante ::
identificación
(University of Montpellier. Department of Respiratory Diseases)
